Insmed Incorporated
INSM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19.2% | 24.4% | 30.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 76.4% | 78.5% | 77.5% | 76.6% |
| R&D Expenses | $1 | $1 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$0 | -$0 |
| % Margin | -241.5% | -232.5% | -186.4% | -199% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$1 | -$1 | -$0 | -$0 |
| % Margin | -251.2% | -245.6% | -196.3% | -230.6% |
| EPS | -5.57 | -5.34 | -3.91 | -3.88 |
| % Growth | -4.3% | -36.6% | -0.8% | – |
| EPS Diluted | -5.57 | -5.34 | -3.91 | -3.88 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$0 | -$0 |
| % Margin | -225.1% | -216.3% | -182.3% | -203.6% |